Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers

NCT05278195 · clinicaltrials.gov ↗
UNKNOWN
Status
300
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Zhongda Hospital